Tameside General Hospital Trials

Tameside General Hospital	Welcome, Profile Billing Logout

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Jude, Edward

FIND-IT, NCT04653545: Diabetes Diagnosis During Acute Admissions

Recruiting

N/A

10000

Europe

HbA1c, Foot examination and other screening for diabetes complications, Lipds and renal function

Tameside General Hospital

Diabete Type 2

09/24

NCT06695325: Convenient Home Access for Routine Monitoring in Diabetes (Charm-D Study)

Not yet recruiting

N/A

300

Europe

HbA1c test

Tameside General Hospital, Roche Diagnostic Ltd.

Diabetes Mellitus

12/25

Harris, Margaret

ASCERTAIN, NCT05834673: VICTORION- Implementation Study (v-)

Terminated

N/A

RoW

SMS messages, Monthly Text Messages, Telephone-based support calls, Nurse Support Calls, GP Education

Monash University, Novartis Pharmaceuticals

Atherosclerotic Cardiovascular Disease (ASCVD), Coronary Heart Disease (CHD), Cerebrovascular Disease, Peripheral Arterial Disease (PAD)

12/24

Person, Contact

PATCH, NCT00303784 / 2005-001030-33: Prostate Adenocarcinoma TransCutaneous Hormones

Recruiting

2200

Europe

Goserelin, Zoladex, Estradiol, FemSeven

University College, London, Medical Research Council

Anemia, Cardiovascular Complications, Hot Flashes, Osteoporosis, Prostate Cancer

08/21

UKALL14, NCT01085617 / 2009-012717-22: Standard Chemotherapy With or Without Nelarabine or Rituximab in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Active, not recruiting

1033

palifermin, rituximab, cyclophosphamide, cytarabine, daunorubicin hydrochloride, etoposide, fludarabine phosphate, imatinib mesylate, melphalan, mercaptopurine, methotrexate, nelarabine, pegaspargase, vincristine sulfate, allogeneic hematopoietic stem cell transplantation, total-body irradiation

University College, London

Leukemia, Mucositis, Oral Complications

12/24

12/25

STAMPEDE, NCT00268476: Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy

Active, not recruiting

2/3

11992

Europe

Celecoxib, Celebrex, Docetaxel, Taxotere, Prednisolone, Prednisone, ADT, Androgen Deprivation Therapy, Zoledronic Acid, Zometa, Abiraterone, Zytiga, Radiotherapy to the prostate, RT, Enzalutamide, Xtandi, Metformin, Metformin Hydrochloride, Transdermal Oestradiol, Progynova TS

Medical Research Council

Prostate Cancer

03/26

12/30

NCT00589017: Tamoxifen in Treating Patients With Metastatic Bladder Cancer That Did Not Respond to Previous Chemotherapy

Recruiting

US, Europe

tamoxifen citrate, immunohistochemistry staining method, laboratory biomarker analysis

Baylor College of Medicine

Bladder Cancer

07/10

NCT03412643: Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 Signaling

Recruiting

Doxorubicin, Cyclophosphamide, Weekly Paclitaxel, Trastuzumab, Pertuzumab, Celcuity CELx HSF

NSABP Foundation Inc, Celcuity, LLC, Genentech, Inc.

HER2-negative Breast Cancer

10/23

PRISM, NCT03658525: Prostate Radiotherapy Integrated With Simultaneous MRI (The Study)

Recruiting

N/A

Europe

MR LINAC

Royal Marsden NHS Foundation Trust

Prostate Cancer

08/20

08/23

NCT06032663: Use of PET-MR in Head and Neck Cancer Patients - Diagnostic and Therapeutic Applications

Recruiting

N/A

Europe

PET-MRI

Sheffield Teaching Hospitals NHS Foundation Trust

Head and Neck Cancer

10/24

10/25

NCT01840293: Breast Cancer Proteomics and Molecular Heterogeneity

Recruiting

N/A

1780

Europe

Cancer Trials Ireland

Primary Breast Cancer, Recurrent/Metastatic Breast Cancer

12/29

01/38

Mihailescu, Andrei

LBF8-Open, NCT04059640: PMCF Study of LiquiBand FIX8® OHMF Device

Recruiting

N/A

107

Europe

LiquiBand FIX8 Open Hernia Mesh Fixation Device

Advanced Medical Solutions Ltd., Imarc Research, Inc.

Inguinal Hernia

05/25

08/25



	Diseases Companies Products Productz Mechanisms of Action Sites